GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneering company in the revolutionary gene-editing technology CRISPR. Its stock price is a speculative bet on the future of medicine. The chart reflects not revenue, but news about clinical trials and investor confidence in the technology's potential.
Share prices of companies in the market segment - Dna
CRISPR Therapeutics is a pioneering company in the field of CRISPR gene editing. We classify it as part of the DNA sector. The chart below shows the overall dynamics of this segment, reflecting investor sentiment regarding this revolutionary genetic technology.
Broad Market Index - GURU.Markets
CRISPR Therapeutics is a leading biotech company using the revolutionary CRISPR/Cas9 gene editing technology to create new drugs. As a pioneer in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors view the future of genetic medicine.
Change in the price of a company, segment, and market as a whole per day
CRSP - Daily change in the company's share price CRISPR Therapeutics AG
Change_Co for CRISPR Therapeutics (CRSP), a leader in gene editing (CRISPR-Cas9), reflects hypersensitivity to clinical results, regulatory milestones, and partnerships. CRSP volatility is a measure of the extreme volatility inherent in breakthrough biotechnologies. This metric is critical for formulaic modeling of risks and potential in the DNA therapeutics sector.
Daily change in the price of a set of shares in a market segment - Dna
CRISPR Therapeutics AG is a pioneer in gene editing. This chart illustrates the extreme volatility of the biotech sector. Comparing it to CRSP, which is a near-pure bet on the success of CRISPR technology, clearly demonstrates its extreme risks.
Daily change in the price of a broad market stock, index - GURU.Markets
CRISPR Therapeutics is a pioneering company in the field of CRISPR gene editing. This is one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CRISPR Therapeutics AG
CRISPR Therapeutics, a pioneer in genome editing technology, achieved historic success last year with the approval of its first drug. Its year-over-year share price performance, shown in the chart, directly reflects this revolution in medicine.
Annual dynamics of market capitalization of the market segment - Dna
CRISPR Therapeutics AG is a leading company developing drugs based on the revolutionary CRISPR gene-editing technology. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field of biotechnology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CRISPR Therapeutics is a pioneer in revolutionary gene editing technology. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most cutting-edge fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CRISPR Therapeutics AG
The performance of CRISPR Therapeutics, a pioneer in gene editing, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about clinical trials of its gene therapy, regulatory approvals, and overall progress in this revolutionary, yet still emerging, field of medicine.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the biotech sector, particularly in gene editing, where CRISPR is a pioneer. Its volatility reflects not current revenues, but rather investor expectations surrounding the revolutionary potential of its technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CRISPR Therapeutics AG is a pioneer in revolutionary gene editing technology, developing treatments for serious diseases. The company's future depends solely on scientific breakthroughs and clinical successes. The broader market chart serves as a mere backdrop to illustrate how news about its cutting-edge technology has driven its stock in its own unique, independent world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in the field of genome editing. Its weekly price action epitomizes biotech volatility. Any news about clinical trials, scientific breakthroughs, or patents triggers extreme price fluctuations. The chart reflects the enormous risks and hopes associated with this technology.
Weekly dynamics of market capitalization of the market segment - Dna
CRISPR Therapeutics is part of the revolutionary gene editing sector. The entire segment can experience ups and downs amid major scientific publications or ethical debates that influence how the technology is perceived. This chart shows how CRISPR is moving with this wave of innovation.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CRISPR Therapeutics is a pioneer in genome editing. The stock price of such companies is driven not by employment reports, but by news of scientific breakthroughs. The chart clearly demonstrates how often the company's weekly performance diverges from the broader market. How immune is it to macroeconomic factors?
Market capitalization of the company, segment and market as a whole
CRSP - Market capitalization of the company CRISPR Therapeutics AG
The CRISPR Therapeutics chart is a visual representation of the revolution in genome editing. Its market cap doesn't reflect current revenues, but rather investors' bets on the future of medicine. Every movement on the chart reflects scientific breakthroughs and the potential of CRISPR technology to treat genetic diseases.
CRSP - Share of the company's market capitalization CRISPR Therapeutics AG within the market segment - Dna
CRISPR Therapeutics is a leading company in the revolutionary field of gene editing. Its share of the biotech sector's market capitalization is based on the enormous potential of CRISPR/Cas9 technology. The chart below illustrates the investors' belief that its developments could lead to cures for a wide range of genetic diseases.
Market capitalization of the market segment - Dna
CRISPR Therapeutics is at the forefront of genetic engineering. But how big is this revolutionary sector? The chart below is a barometer of DNA-based biotechnology. Its dramatic ups and downs reflect the hopes and risks associated with a technology potentially worth trillions.
Market capitalization of all companies included in a broad market index - GURU.Markets
The CRISPR Therapeutics chart shows the value of one of the most breakthrough technologies in medicine—gene editing. The company's market capitalization isn't based on current sales, but rather on the market's belief in its ability to create cures for genetic diseases. Every jump in the chart reflects clinical successes and scientific discoveries.
Book value capitalization of the company, segment and market as a whole
CRSP - Book value capitalization of the company CRISPR Therapeutics AG
For CRISPR Therapeutics, a pioneer in genome editing, book value is its tangible foundation: cutting-edge laboratories, scientific equipment, and significant cash reserves to fund research. The chart below shows how this physical and financial capital, which underpins this revolutionary technology, has grown.
CRSP - Share of the company's book capitalization CRISPR Therapeutics AG within the market segment - Dna
CRISPR Therapeutics is at the forefront of genetic engineering, and its resources include state-of-the-art laboratories and pilot production facilities. It is in these clean rooms that the future of medicine is being created. The chart below shows the share of this unique, science-intensive infrastructure the company controls in its revolutionary sector.
Market segment balance sheet capitalization - Dna
CRISPR Therapeutics is a pioneer in gene editing. Its value lies in its patents and scientific discoveries, not its factories. The chart below reflects the enormous capital intensity of the pharmaceutical sector, clearly demonstrating how lightweight and science-intensive its business model is.
Book value of all companies included in the broad market index - GURU.Markets
CRISPR Therapeutics is a pioneer in genome editing. The company's assets include laboratories and scientific equipment. Its modest stake in BCap_All provides a material foundation for a technology that has the potential to revolutionize medicine and create immeasurable value in the future.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CRISPR Therapeutics AG
CRISPR Therapeutics has minimal physical assets. Its market valuation is hundreds of times higher than its book value. This gap is the price of believing in a revolution. Investors are buying not equipment, but a patent for a genome-editing technology that could one day cure genetic diseases.
Market to book capitalization ratio in a market segment - Dna
CRISPR Therapeutics is a leading gene editing company. Its book value is minimal compared to its market capitalization, which is based on the revolutionary potential of CRISPR/Cas9 technology. This metric reflects the enormous investor expectations for future therapies.
Market to book capitalization ratio for the market as a whole
CRISPR Therapeutics is a pioneer in the revolutionary CRISPR/Cas9 gene editing technology, and its value lies almost entirely in its intellectual property. This chart shows the average market valuation. Against this backdrop, CRISPR's premium appears colossal, as investors value not current assets but the potential to transform medicine in the future.
Debts of the company, segment and market as a whole
CRSP - Company debts CRISPR Therapeutics AG
CRISPR Therapeutics, a pioneer in gene editing, funds its revolutionary research through leveraged capital. The company's debt strategy is aimed at supporting lengthy and extremely expensive clinical trials. Its commitment schedule is a financial reflection of its bold investments in developing therapies for previously incurable diseases.
Market segment debts - Dna
CRISPR Therapeutics is a leading company in the field of genome editing. This is a cutting-edge, but still largely research-based, area of biotechnology. Financing here is typically equity-based, as the risks are too high for traditional lenders. This chart shows whether the company is following the industry-standard model or has found other sources of capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in gene editing, a technology with revolutionary potential but requiring massive investment in research. This chart shows the company's financial structure, demonstrating its reliance on equity rather than debt, which is typical for biotech companies in the pre-commercialization stage.
Market segment debt to market segment book capitalization - Dna
CRISPR Therapeutics is a pioneer in gene editing, developing treatments for serious diseases. This chart shows the collective debt burden of the cutting-edge gene therapy sector. It provides insight into how the industry as a whole finances its expensive and time-consuming research, and how CRISPR's financial strategy compares against this backdrop.
Debt to book value of all companies in the market
CRISPR Therapeutics is a pioneer in gene editing, a sector with enormous capital requirements and high risks. This chart shows the overall risk appetite across the market. It helps us understand how favorable the macroeconomic environment is to funding revolutionary, but very long-term and expensive, projects like CRISPR.
P/E of the company, segment and market as a whole
P/E - CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene editing company developing CRISPR-based therapies. This chart illustrates that the company's valuation is based on the enormous potential of its scientific platform, not on current revenue. Investors are betting on a future revolution in the treatment of genetic diseases.
P/E of the market segment - Dna
Genome-editing companies like CRISPR Therapeutics are at the forefront of biotech. This chart shows the average valuation for more mature biotechs. It provides context, making it clear that CRISPR is not valued based on profits, but rather as a revolutionary platform with the potential to be valued many times higher than current industry standards.
P/E of the market as a whole
CRISPR Therapeutics is a leading gene editing company. Its valuation is a bet on a scientific revolution in medicine. It has no significant revenue and is entirely dependent on the success of clinical trials. Therefore, its value can fluctuate by tens of percent daily based on lab news, while ignoring any general market trends shown on this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in revolutionary gene editing technology. For a company in the research stage, this chart is especially important. It reflects not so much current sales as analysts' expectations for clinical trial results and the potential approval of breakthrough treatments. Every move here is a bet on scientific success and future revenue.
%20P%2FE%20CRISPR%20Therapeutics%20AG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CRISPR-Therapeutics-AG&v=1772662035029 "Chart of the company's future (projected) P/E CRISPR Therapeutics AG")
Future (projected) P/E of the market segment - Dna
CRISPR Therapeutics is a leading company developing drugs based on the revolutionary CRISPR/Cas9 gene editing technology. The chart shows how market expectations for the company's profitability compare to the biotech sector. This reflects investor confidence in the long-term potential of its platform for treating a wide range of genetic diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772662035253 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
CRISPR Therapeutics is one of the leading companies in the field of genome editing. This chart shows the overall risk appetite. CRISPR's valuation is based on the revolutionary potential of its technology, not on current revenue. A positive market environment helps fund research, but the real driver is successful clinical trials that have the potential to transform medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772662035482 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CRISPR Therapeutics AG
CRISPR Therapeutics is one of the leading companies developing drugs based on the revolutionary CRISPR/Cas9 gene editing technology. This chart illustrates the financial trajectory of this biotech pioneer. Current results reflect the enormous investment in research that could lead to the development of therapies for previously incurable diseases.
Profit of companies in the market segment - Dna
CRISPR Therapeutics is one of the leading companies using the revolutionary CRISPR/Cas9 gene editing technology to create treatments for serious diseases. It is at the forefront of genetic medicine. This chart illustrates the financial climate in the gene therapy sector, demonstrating the level of confidence among investors and the market in the commercial potential of this breakthrough technology.
Overall market profit
CRISPR Therapeutics is a pioneer in gene editing. The company's value is based on the potential of its revolutionary technology to cure genetic diseases. This business operates in the world of science and clinical trials, far removed from quarterly fluctuations in GDP. However, the overall market backdrop, as illustrated here, influences investor appetite for such long-term stories.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in the revolutionary CRISPR/Cas9 gene editing technology. The company aims to develop treatments for severe genetic diseases. The revenue projections presented here are long-term estimates based on the assumption that its therapeutic approaches are approved and commercialized.
%20profit%20of%20the%20company%20CRISPR%20Therapeutics%20AG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CRISPR-Therapeutics-AG&v=1772662036052 "Graph of future (projected) profit of the company CRISPR Therapeutics AG")
Future (predicted) profit of companies in the market segment - Dna
CRISPR Therapeutics is a pioneer in gene editing using CRISPR/Cas9 technology. This chart reflects the outlook for the biotech sector, which is filled with both enormous promise and risks. The company's potential to treat genetic diseases is enormous, but its value depends entirely on future success in clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772662036250 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
CRISPR Therapeutics is a pioneer in gene editing. The company's success depends on scientific breakthroughs, not economic cycles. However, this graph of projected market returns is critically important. It reflects investors' appetite for high-risk assets. During periods of rising profits, capital is more likely to flow into biotech, funding expensive CRISPR research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772662036258 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene editing company. Because its products are still in development, this chart reflects not current revenue but rather the enormous expectations of investors. It shows how the market perceives the potential of CRISPR technology to transform medicine and generate billions in revenue in the future.
P/S market segment - Dna
CRISPR Therapeutics is a leading company developing CRISPR/Cas9 gene editing technology for the treatment of severe diseases. Its valuation is based on future potential. This chart reflects the average valuation in the biotech sector, providing insight into how high investor expectations for the CRISPR platform are compared to other innovative companies.
P/S of the market as a whole
CRISPR Therapeutics is a leading company using CRISPR/Cas9 gene editing technology to create new treatments for severe diseases. Its valuation is based on future potential. This graph of average market revenue estimates clearly illustrates how far removed the valuations of pioneering biotech companies are from their current revenues.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in gene editing, developing drugs based on CRISPR/Cas9 technology. For a company at the forefront of science, this graph reflects expectations of enormous future revenue. It is highly sensitive to clinical trial results and the potential of its platform for treating genetic diseases.
%20P%2FS%20CRISPR%20Therapeutics%20AG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CRISPR-Therapeutics-AG&v=1772662036345 "The graph of the company's future (projected) P/S CRISPR Therapeutics AG")
Future (projected) P/S of the market segment - Dna
CRISPR Therapeutics is a pioneer in the field of CRISPR/Cas9 gene editing, developing therapies for the treatment of genetic diseases. This chart reflects the high expectations of investors for the future of this revolutionary technology. It balances the potential for future sales with the high risks and long road to commercialization.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772662036356 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
CRISPR Therapeutics is a leading company developing drugs based on the revolutionary CRISPR/Cas9 gene editing technology. This graph reflects expectations for existing markets, while CRISPR is creating future markets. The potential of this technology for treating genetic diseases is enormous, and the company's success could lead to exponential revenue growth for the entire biopharma industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772662036369 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene editing company. Currently, its revenue is generated not from sales of its own products, but from multimillion-dollar payments from major pharmaceutical partners for the joint development of therapies. This chart reflects the financial success of these strategic alliances.
Sales of companies in the market segment - Dna
CRISPR Therapeutics is a pioneer in gene editing, developing drugs based on CRISPR/Cas9 technology. Their clinical successes could lead to the development of treatments for previously incurable diseases. This graph reflects the cumulative expectations and investments in the revolutionary field of genetic engineering, where CRISPR is a key innovator.
Overall market sales
CRISPR Therapeutics, a leading genome editing company, operates at the cutting edge of science. Its success depends on the investment climate. Periods of revenue growth, as reflected in the graph, create a surplus of capital that investors are willing to allocate to breakthrough but risky biotech projects, funding expensive CRISPR research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CRISPR Therapeutics AG
CRISPR Therapeutics is a leading company developing gene therapy based on the revolutionary CRISPR/Cas9 technology. The forecast for future sales reflects analysts' bets that its developments for treating genetic diseases such as sickle cell anemia will receive regulatory approval and be commercially successful, ushering in a new era of medicine.
%20sales%20of%20the%20company%20CRISPR%20Therapeutics%20AG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CRISPR-Therapeutics-AG&v=1772662036428 "Schedule of future (projected) sales of the company CRISPR Therapeutics AG")
Future (projected) sales of companies in the market segment - Dna
CRISPR Therapeutics is a leading gene editing company, using CRISPR/Cas9 technology to create new treatments for genetic diseases. It is at the forefront of medical science. This chart displays forecasts for the entire biotech sector, allowing you to assess how market expectations compare to the breakthrough potential of CRISPR.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772662036434 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
For CRISPR Therapeutics, a pioneer in gene editing, this chart is important as an indicator of risk appetite in biotech. Breakthrough technologies require massive investment. The positive economic forecasts reflected here create a favorable environment for attracting the capital needed to conduct expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772662036455 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CRISPR Therapeutics AG
CRISPR Therapeutics is one of the leading companies working with CRISPR/Cas9 genome editing technology. Being at the forefront of science, the company incurs significant expenditures on research and clinical trials. This metric reflects its current financial status: is it still in the process of major investments in the future or is it already beginning to profit from technology commercialization?
Market segment marginality - Dna
CRISPR Therapeutics is a leading biotechnology company specializing in the development of transformative drugs based on the revolutionary CRISPR/Cas9 gene editing technology. This chart illustrates its financial performance within the biotech sector. Its high margins at this stage may be due to large upfront payments from joint development partners.
Market marginality as a whole
CRISPR Therapeutics is a pioneer in genome editing, a technology with the potential to cure inherited diseases. This chart reflects today's profitability, while CRISPR is focused on the day after tomorrow. Their financial performance represents an investment in a scientific revolution that could yield a completely different level of profitability in the future.
Employees in the company, segment and market as a whole
Number of employees in the company CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in revolutionary genome editing technology. This graph visualizes the growth of its scientific potential. Each increase in staff means expanding research, launching new clinical programs, and getting closer to creating cures for previously incurable genetic diseases. This is a team changing medicine.
Share of the company's employees CRISPR Therapeutics AG within the market segment - Dna
CRISPR Therapeutics is a pioneer in genome editing, a technology with the potential to transform medicine. Its primary resource is the world's best minds in genetic engineering. The data in this chart shows the company's share of all scientists in this cutting-edge sector, a direct reflection of its scientific leadership and potential for creating revolutionary therapies.
Number of employees in the market segment - Dna
CRISPR Therapeutics is a pioneer in gene editing. Its core asset is its team of leading scientists and researchers. This chart shows the growth of intellectual capital, which directly correlates with the progress of therapeutic programs through clinical trials. For investors, this is a key indicator of progress in developing breakthrough drugs.
Number of employees in the market as a whole
CRISPR Therapeutics is a pioneer in gene editing. It is a science-intensive company whose success depends on research results and regulatory approval. Its staff consists of leading scientists. Given the overall labor market dynamics visible in this graph, CRISPR represents the vanguard of biotechnology, creating jobs that will shape the future of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a pioneer in gene editing. With a small staff of elite scientists, the company boasts a huge market capitalization thanks to the potential of its revolutionary technology. This chart shows the astronomical cost per employee, as investors value future medical revolutions rather than current revenues.
%20of%20the%20company%20CRISPR%20Therapeutics%20AG%20(CRSP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CRISPR-Therapeutics-AG-CRSP&v=1772662036580 "Chart of market capitalization per employee (in thousands of dollars) of the company CRISPR Therapeutics AG (CRSP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
CRISPR Therapeutics is one of the leading companies developing drugs based on the revolutionary CRISPR/Cas9 gene editing technology. This is pure science at the cutting edge of progress. This chart reflects the average capitalization per employee in the sector. It demonstrates the market's astronomical faith in their technological platform and team of scientists, who have the potential to transform medicine.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772662036592 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
CRISPR Therapeutics is a pioneer in gene editing. It is a science-intensive company whose value is based on the potential of its revolutionary CRISPR/Cas9 technology. The data presented demonstrates an extremely high market valuation per employee, as the intellectual contribution of a small team of scientists can lead to the creation of cures for previously incurable diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772662036607 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a pioneer in gene editing (CRISPR-Cas9). It's pure biotechnology. At this stage, this metric doesn't reflect profit, but rather the capital burned on research. However, it does reflect a bet that a small team of elite scientists will create a therapy that will transform medicine and generate colossal profits in the future.
%20Chart%20CRISPR%20Therapeutics%20AG%20(CRSP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CRISPR-Therapeutics-AG-CRSP&v=1772662036628 "Company Profit Per Employee (in thousands of dollars) Chart CRISPR Therapeutics AG (CRSP)")
Profit per employee (in thousands of dollars) in the market segment - Dna
CRISPR Therapeutics is a pioneer in genome editing (CRISPR). This graph shows the benchmark for DNA (Biotech). In this sector, the benchmark is likely *negative*. Companies are burning billions on R&D. Profit per employee (elite scientist) is a distant goal, should this revolutionary technology succeed.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772662036649 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
CRISPR Therapeutics (CRSP) is a leading company using CRISPR/Cas9 gene editing technology to create transformative treatments for genetic diseases such as sickle cell anemia. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772662036664 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a leading gene editing company. At this stage of its development, this chart reflects strategic successes rather than sales. Revenue per employee typically comes from partnerships with major pharmaceutical companies and is an indicator of progress in clinical trials of their revolutionary technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CRISPR-Therapeutics-AG-CRSP&v=1772662036676 "Sales chart per company employee CRISPR Therapeutics AG (CRSP)")
Sales per employee in the market segment - Dna
CRISPR Therapeutics is at the forefront of genetic engineering using CRISPR/Cas9 technology. As with any cutting-edge biotech, the focus has shifted from R&D to commercialization. This chart shows the average revenue per employee in the segment. It provides an idea of how effectively the company can scale its breakthrough technologies using its team compared to other biotech firms.
Sales per employee for the market as a whole
CRISPR Therapeutics AG is a pioneer in the field of CRISPR/Cas9 gene editing. It's a science-intensive business, where the majority of the team is made up of scientists. This graph shows the moment of truth: when intellectual labor begins to pay off. It reflects the revenue (from partnerships or initial sales) generated per employee as the company begins to monetize its revolutionary technology.
Short shares by company, segment and market as a whole
Shares shorted by company CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a pioneer in gene editing, developing treatments based on CRISPR/Cas9 technology. This is a breakthrough, but it comes with enormous risks. The chart shows the number of investors who are skeptical of the company's astronomical valuation, fearing trial failures, fierce competition, or regulatory barriers to commercialization.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CRISPR-Therapeutics-AG-CRSP&v=1772662036724 "Short Shares Chart for the Company CRISPR Therapeutics AG (CRSP)")
Shares shorted by market segment - Dna
CRISPR Therapeutics is a pioneer in gene editing, a technology with enormous potential and risks. This chart shows the total volume of short positions across the gene therapy sector. Its growth signals general investor skepticism about this cutting-edge, yet unproven, technology and its commercial prospects.
Shares shorted by the overall market
CRISPR Therapeutics (CRSP) is a pioneer in gene editing. It's one of the most speculative areas of biotech. The Short_All indicator is a mirror of fear. When it rises, investors panic and dump "story stocks" that are burning money. This pessimism, visible on the chart, deprives CRSP of vital capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a pioneer in CRISPR gene editing. This is a highly speculative R&D story. A CRSP above 70 may reflect CRISPR hype or positive trial data. A CRSP below 30 is often associated with failures, regulatory hurdles, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CRISPR-Therapeutics-AG-CRSP&v=1772662036785 "RSI 14 indicator chart for the company's stock CRISPR Therapeutics AG (CRSP)")
RSI 14 Market Segment - Dna
CRISPR Therapeutics (CRSP) is at the forefront of a medical revolution, using gene-editing technology (CRISPR/Cas9) to treat serious diseases. It's a sector with binary risk: either massive success or failure. This chart tracks the collective sentiment in the genomic technologies sector. It shows when the entire industry is overheated by hype around breakthroughs or oversold by failures, providing context for evaluating CRSP.
RSI 14 for the overall market
CRISPR Therapeutics is a pioneer in gene editing (CRISPR/Cas9). It's a revolutionary technology, but the company is still in the R&D stage. Its survival depends on funding. This chart, showing risk appetite, is everything to them. Euphoria allows investors to "buy the future," while panic "shuts off" access to capital.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRSP (CRISPR Therapeutics AG)
CRISPR Therapeutics is a gene editing pioneer using CRISPR/Cas9 technology to create transformative treatments for genetic diseases such as sickle cell anemia. This chart shows the average price target from analysts, reflecting their expectations for the therapy's revolutionary potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRSP-CRISPR-Therapeutics-AG&v=1772662036885 "A chart showing analyst consensus forecasts for the expected stock price. CRSP (CRISPR Therapeutics AG)")
The difference between the consensus estimate and the actual stock price CRSP (CRISPR Therapeutics AG)
CRISPR Therapeutics is a pioneer in revolutionary gene editing technology (CRISPR/Cas9). They just received approval for their first drug (Casgevy) for sickle cell anemia. This chart shows analysts' confidence in the commercial success of this launch and their future pipeline. It reflects the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRSP-CRISPR-Therapeutics-AG&v=1772662036889 "A chart showing the difference between the consensus forecast and the actual stock price. CRSP (CRISPR Therapeutics AG)")
Analyst consensus forecast for stock prices by market segment - Dna
CRISPR Therapeutics is a pioneer in gene editing, using CRISPR/Cas9 technology to create treatments for genetic diseases (such as sickle cell anemia). This chart shows general expectations for the DNA technology sector, reflecting whether experts believe this revolutionary science will be commercially successful.
Analysts' consensus forecast for the overall market share price
CRISPR Therapeutics is a pioneer in gene editing. It's an R&D company bordering on science fiction. This chart, reflecting expert expectations, is, for them, a measure of risk appetite. When the market is pessimistic, investors flee cash-burning biotech companies whose payback is decades away.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CRISPR Therapeutics AG
CRISPR Therapeutics is a pioneer in the revolutionary CRISPR/Cas9 gene editing technology. They recently received approval for their first drug (Casgevy). This chart is a summary indicator of their platform valuation. It reflects not current revenue, but the enormous expectations for their ability to apply this technology to treat a wide range of genetic diseases.
AKIMA Market Segment Index - Dna
CRISPR Therapeutics is a pioneer in revolutionary genome editing technology (CRISPR-Cas9). The company literally cures genetic diseases (its first drug, Casgevy, has been approved). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does its futuristic CRISPR R&D platform differentiate it from the average, traditional pharma company?
The AKIM Index for the overall market
CRISPR is a pioneer in genome editing. It's a biotech company on the cusp of a medical revolution (treating genetic diseases). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, stacks up against the backdrop of overall economic trends.
